This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ANX105 administered intravenously (IV) to healthy participants.

Key Inclusion Criteria:

• Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
• Have been fully vaccinated with SARS-CoV-2 vaccination according to local guidelines within 14 days prior to Day -1.
• Documented history of vaccinations within 5 years or willing to undergo vaccinations prior to screening visit against encapsulated bacterial pathogens.

Key Exclusion Criteria:

• Clinically significant infection within 30 days prior to Day -1 that required medical intervention.
• Significant allergies to humanized monoclonal antibodies.
• Use of immunosuppressants including high-dose systemic corticosteroids within 30 days prior to Day -1.
• Antinuclear antibodies (ANA) titer ≥1:160 (for either of the 2 ANA results a minimum of 2 weeks apart) at Screening.
• Have poor venous access limiting phlebotomy.
• Donation or loss of > 500 milliliter whole blood within 30 days prior to Day 1 or donation of plasma within 14 days prior to Day -1.
• Hospitalization during the 4 weeks prior to Screening.